Grb10 is involved in BCR-ABL-positive leukemia in mice

Leukemia

Volumn 29, Issue 4, 2015, Pages 858-868

  Illert, A L ^a   Albers, C ^a,b   Kreutmair, S ^a   Leischner, H ^b,c   Peschel, C ^b   Miething, C ^a   Duyster, J ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c HELIOS KLINIKUM BERLIN BUCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; FLUOROURACIL; GROWTH FACTOR RECEPTOR BOUND PROTEIN 10; IMATINIB; METHYLCELLULOSE; MICRORNA; RETROVIRUS VECTOR; ABL-BCR FUSION PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; GRB10 PROTEIN, MOUSE; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; SMALL INTERFERING RNA;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL VIABILITY; CHRONIC MYELOID LEUKEMIA; COLONY FORMATION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; K562 CELL LINE; MOUSE; NONHUMAN; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; VIRAL GENE DELIVERY SYSTEM; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CELL CYCLE; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; METABOLISM; PATHOLOGY; PRIMARY CELL CULTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZAMIDES; BONE MARROW CELLS; CELL CYCLE; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; FEMALE; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, LEUKEMIC; GRB10 ADAPTOR PROTEIN; HUMANS; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICE; MICE, INBRED BALB C; MICRORNAS; PIPERAZINES; PRIMARY CELL CULTURE; PYRIMIDINES; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 84927611485     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.283     Document Type: Article

References (54)

1. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001; 344: 1031-1037.
2. Bhatia R, Holtz M, Niu N, Gray R, Snyder DS, Sawyers CL et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003; 101: 4701-4707.
3. Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: The prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010; 11: 1029-1035.
4. De Lavallade H, Apperley JF, Khorashad JS, Milojkovic D, Reid AG, Bua M et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: Incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008; 26: 3358-3363.
5. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006; 355: 2408-2417.
6. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006; 354: 2542-2551.
7. Quintas-Cardama A, Kantarjian H, Jones D, Nicaise C, O'Brien S, Giles F et al. Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. Blood 2007; 109: 497-499.
8. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010; 362: 2260-2270.
9. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010; 362: 2251-2259.
10. Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007; 110: 3540-3546.
11. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006; 354: 2531-2541.
12. Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 2011; 12: 841-851.
13. Gontarewicz A, Balabanov S, Keller G, Colombo R, Graziano A, Pesenti E et al. Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I. Blood 2008; 111: 4355-4364.
14. Skorski T, Kanakaraj P, Nieborowska-Skorska M, Ratajczak MZ, Wen SC, Zon G et al. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood 1995; 86: 726-736.
15. Mohi MG, Boulton C, Gu TL, Sternberg DW, Neuberg D, Griffin JD et al. Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc Natl Acad Sci USA 2004; 101: 3130-3135.
16. Klejman A, Rushen L, Morrione A, Slupianek A, Skorski T. Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571. Oncogene 2002; 21: 5868-5876.
17. Yu C, Krystal G, Dent P, Grant S. Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells. Clin Cancer Res 2002; 8: 2976-2984.
18. Peters DG, Hoover RR, Gerlach MJ, Koh EY, Zhang H, Choe K et al. Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia. Blood 2001; 97: 1404-1412.
19. Borthakur G, Kantarjian H, Daley G, Talpaz M, O'Brien S, Garcia-Manero G et al. Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy. Cancer 2006; 106: 346-352.
20. Jahn T, Seipel P, Urschel S, Peschel C, Duyster J. Role for the adaptor protein Grb10 in the activation of Akt. Mol Cell Biol 2002; 22: 979-991.
21. Nantel A, Mohammad-Ali K, Sherk J, Posner BI, Thomas DY. Interaction of the Grb10 adapter protein with the Raf1 and MEK1 kinases. J Biol Chem 1998; 273: 10475-10484.
22. Deng Y, Bhattacharya S, Swamy OR, Tandon R, Wang Y, Janda R et al. Growth factor receptor-binding protein 10 (Grb10) as a partner of phosphatidylinositol 3-kinase in metabolic insulin action. J Biol Chem 2003; 278: 39311-39322.
23. Langlais P, Dong LQ, Hu D, Liu F. Identification of Grb10 as a direct substrate for members of the Src tyrosine kinase family. Oncogene 2000; 19: 2895-2903.
24. Murdaca J, Treins C, Monthouel-Kartmann MN, Pontier-Bres R, Kumar S, Van Obberghen E et al. Grb10 prevents Nedd4-mediated vascular endothelial growth factor receptor-2 degradation. J Biol Chem 2004; 279: 26754-26761.
25. Charalambous M, Smith FM, Bennett WR, Crew TE, Mackenzie F, Ward A. Disruption of the imprinted Grb10 gene leads to disproportionate overgrowth by an Igf2-independent mechanism. Proc Natl Acad Sci USA 2003; 100: 8292-8297.
26. Holt LJ, Turner N, Mokbel N, Trefely S, Kanzleiter T, Kaplan W et al. Grb10 regulates the development of fiber number in skeletal muscle. FASEB J 2012; 26: 3658-3669.
27. Smith FM, Holt LJ, Garfield AS, Charalambous M, Koumanov F, Perry M et al. Mice with a disruption of the imprinted Grb10 gene exhibit altered body composition, glucose homeostasis, and insulin signaling during postnatal life. Mol Cell Biol 2007; 27: 5871-5886.
28. Yu Y, Yoon S-O, Poulogiannis G, Yang Q, Ma XM, Villén J et al. Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science 2011; 332: 1322-1326.
29. Okino K, Konishi H, Doi D, Yoneyama K, Ota Y, Jin E et al. Up-regulation of growth factor receptor-bound protein 10 in cervical squamous cell carcinoma. Oncol Rep 2005; 13: 1069-1074.
30. Casas S, Ollila J, Aventin A, Vihinen M, Sierra J, Knuutila S. Changes in apoptosisrelated pathways in acute myelocytic leukemia. Cancer Genet Cytogenet 2003; 146: 89-101.
31. Kazi JU, Ronnstrand L. FLT3 signals via the adapter protein Grb10 and overexpression of Grb10 leads to aberrant cell proliferation in acute myeloid leukemia. Mol Oncol 2013; 7: 402-418.
32. Gutierrez NC, Lopez-Perez R, Hernandez JM, Isidro I, Gonzalez B, Delgado M et al. Gene expression profile reveals deregulation of genes with relevant functions in the different subclasses of acute myeloid leukemia. Leukemia 2005; 19: 402-409.
33. Diaz-Blanco E, Bruns I, Neumann F, Fischer JC, Graef T, Rosskopf M et al. Molecular signature of CD34(+) hematopoietic stem and progenitor cells of patients with CML in chronic phase. Leukemia 2007; 21: 494-504.
34. Bai RY, Jahn T, Schrem S, Munzert G, Weidner KM, Wang JY et al. The SH2-containing adapter protein GRB10 interacts with BCR-ABL. Oncogene 1998; 17: 941-948.
35. Von Bubnoff N, Veach DR, Van Der Kuip H, Aulitzky WE, Sanger J, Seipel P et al. A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor. Blood 2005; 105: 1652-1659.
36. Albers C, Illert AL, Miething C, Leischner H, Thiede M, Peschel C et al. An RNAi-based system for loss-of-function analysis identifies Raf1 as a crucial mediator of BCR-ABL-driven leukemogenesis. Blood 2011; 118: 2200-2210.
37. Miething C, Feihl S, Mugler C, Grundler R, Von Bubnoff N, Lordick F et al. The Bcr-Abl mutations T315I and Y253H do not confer a growth advantage in the absence of imatinib. Leukemia 2006; 20: 650-657.
38. Haferlach T, Kohlmann A, Wieczorek L, Basso G, Kronnie GT, Bene MC et al. Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: Report from the International Microarray Innovations in Leukemia Study Group. J Clin Oncol 2010; 28: 2529-2537.
39. Coustan-Smith E, Song G, Clark C, Key L, Liu P, Mehrpooya M et al. New markers for minimal residual disease detection in acute lymphoblastic leukemia. Blood 2011; 117: 6267-6276.
40. Maia S, Haining WN, Ansen S, Xia Z, Armstrong SA, Seth NP et al. Gene expression profiling identifies BAX-delta as a novel tumor antigen in acute lymphoblastic leukemia. Cancer Res 2005; 65: 10050-10058.
41. Zeng Y, Wagner EJ, Cullen BR. Both natural and designed micro RNAs can inhibit the expression of cognate mRNAs when expressed in human cells. Mol Cell 2002; 9: 1327-1333.
42. Silva JM, Li MZ, Chang K, Ge W, Golding MC, Rickles RJ et al. Second-generation shRNA libraries covering the mouse and human genomes. Nat Genet 2005; 37: 1281-1288.
43. Stegmeier F, Hu G, Rickles RJ, Hannon GJ, Elledge SJ. A lentiviral microRNA-based system for single-copy polymerase II-regulated RNA interference in mammalian cells. Proc Natl Acad Sci USA 2005; 102: 13212-13217.
44. Zeng Y, Cai X, Cullen BR. Use of RNA polymerase II to transcribe artificial microRNAs. Methods Enzymol 2005; 392: 371-380.
45. Li S, Ilaria RL Jr, Million RP, Daley GQ, Van Etten RA. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med 1999; 189: 1399-1412.
46. Van Etten RA. Retroviral transduction models of Ph+ leukemia: Advantages and limitations for modeling human hematological malignancies in mice. Blood Cells Mol Dis 2001; 27: 201-205.
47. Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 2005; 5: 172-183.
48. Jiang X, Stuible M, Chalandon Y, Li A, Chan WY, Eisterer W et al. Evidence for a positive role of SHIP in the BCR-ABL-mediated transformation of primitive murine hematopoietic cells and in human chronic myeloid leukemia. Blood 2003; 102: 2976-2984.
49. Sattler M, Mohi MG, Pride YB, Quinnan LR, Malouf NA, Podar K et al. Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell 2002; 1: 479-492.
50. Di Cristofano A, Niki M, Zhao M, Karnell FG, Clarkson B, Pear WS et al. p62(dok), a negative regulator of Ras and mitogen-activated protein kinase (MAPK) activity, opposes leukemogenesis by p210(bcr-abl). J Exp Med 2001; 194: 275-284.
51. Kebache S, Ash J, Annis MG, Hagan J, Huber M, Hassard J et al. Grb10 and active Raf-1 kinase promote Bad-dependent cell survival. J Biol Chem 2007; 282: 21873-21883.
52. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995; 270: 1326-1331.
53. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature 2001; 410: 37-40.
54. Aceves-Luquero CI, Agarwal A, Callejas-Valera JL, Arias-Gonzalez L, Esparis-Ogando A, del Peso Ovalle L et al. ERK2, but not ERK1, mediates acquired and "de novo" resistance to imatinib mesylate: Implication for CML therapy. PLoS One 2009; 4: E6124.